DE60013630D1 - Arzneimittel zur behandlung von darmverstopfung und reizkolon - Google Patents

Arzneimittel zur behandlung von darmverstopfung und reizkolon

Info

Publication number
DE60013630D1
DE60013630D1 DE60013630T DE60013630T DE60013630D1 DE 60013630 D1 DE60013630 D1 DE 60013630D1 DE 60013630 T DE60013630 T DE 60013630T DE 60013630 T DE60013630 T DE 60013630T DE 60013630 D1 DE60013630 D1 DE 60013630D1
Authority
DE
Germany
Prior art keywords
colon
irritary
construction
treatment
medicinal products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60013630T
Other languages
English (en)
Other versions
DE60013630T2 (de
Inventor
John Rhodes
Brian Kenneth Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9925872A external-priority patent/GB9925872D0/en
Priority claimed from GB9928314A external-priority patent/GB9928314D0/en
Application filed by Individual filed Critical Individual
Publication of DE60013630D1 publication Critical patent/DE60013630D1/de
Application granted granted Critical
Publication of DE60013630T2 publication Critical patent/DE60013630T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
DE60013630T 1999-11-01 2000-10-30 Arzneimittel zur behandlung von darmverstopfung und reizkolon Expired - Lifetime DE60013630T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9925872A GB9925872D0 (en) 1999-11-01 1999-11-01 Composition for relief of constipation
GB9925872 1999-11-01
GB9928314A GB9928314D0 (en) 1999-11-30 1999-11-30 Composition for the treatment of irritable bowel syndrome
GB9928314 1999-11-30
PCT/GB2000/004167 WO2001032180A2 (en) 1999-11-01 2000-10-30 Composition for treatment of constipation and irritable bowel syndrome

Publications (2)

Publication Number Publication Date
DE60013630D1 true DE60013630D1 (de) 2004-10-14
DE60013630T2 DE60013630T2 (de) 2005-09-15

Family

ID=26316047

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60013630T Expired - Lifetime DE60013630T2 (de) 1999-11-01 2000-10-30 Arzneimittel zur behandlung von darmverstopfung und reizkolon

Country Status (14)

Country Link
US (1) US6734188B1 (de)
EP (1) EP1225897B1 (de)
JP (1) JP2003513045A (de)
AT (1) ATE275402T1 (de)
AU (1) AU776567B2 (de)
CA (1) CA2389650C (de)
CZ (1) CZ299726B6 (de)
DE (1) DE60013630T2 (de)
DK (1) DK1225897T3 (de)
ES (1) ES2226933T3 (de)
HK (1) HK1048595A1 (de)
IL (2) IL149378A0 (de)
PT (1) PT1225897E (de)
WO (1) WO2001032180A2 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2241458C2 (ru) 1997-12-22 2004-12-10 Эро-Селтик, С.А. Комбинации агонист/антагонист опиоида
AU776567B2 (en) 1999-11-01 2004-09-16 Evans, Brian K Composition for treatment of constipation and irritable bowel syndrome
SI2517710T1 (sl) 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
JP4522652B2 (ja) 2001-05-11 2010-08-11 エンドー ファーマシューティカルズ， インコーポレイティド 乱用防止制御放出オピオイド投薬形態
AU2002316738B2 (en) 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
MXPA04001210A (es) 2001-08-06 2004-07-08 Euro Celtique Sa Formulaciones de agonista opioide con antagonista liberable y aislado.
JP4620355B2 (ja) 2002-04-05 2011-01-26 ユーロ−セルティーク エス．エイ． 活性化合物の持続、不変及び独立放出のためのマトリクス
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
CN1703200B (zh) 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
BR122018074353B8 (pt) 2003-01-28 2021-07-27 Ironwood Pharmaceuticals Inc composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
JP5032300B2 (ja) * 2004-03-22 2012-09-26 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物
CA2594987A1 (en) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. Therapeutic agent for constipation
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662390B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
RU2413532C2 (ru) 2005-07-29 2011-03-10 Зольвай Фармасьютиклз Гмбх Способ получения стерилизованного порошкообразного панкреатина
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
JP2009534384A (ja) * 2006-04-19 2009-09-24 ジル・ピー・スミス オピオイドアンタゴニストによる炎症性および潰瘍性腸疾患の治療
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
DK2719378T3 (en) 2006-06-19 2016-10-17 Alpharma Pharmaceuticals Llc pharmaceutical compositions
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
AU2006348180A1 (en) * 2006-09-13 2008-03-20 Warner Chilcott Company, Llc Methods of treatment for ulcerative colitis
BRPI0622007A2 (pt) * 2006-09-13 2011-12-20 Procter & Gamble uso de aminossalicilato para tratar colite ulcerativa
ES2493590T3 (es) 2007-03-29 2014-09-12 Wyeth Llc Antagonistas de receptores opioides periféricos y usos de los mismos
WO2008121348A2 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
CA2682129A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN101772513B (zh) 2007-06-04 2013-11-13 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
EP2214672B1 (de) * 2007-10-18 2012-10-17 Aiko Biotechnology Kombinationsanalgetikum mit einem opioid und einem neutralen antagonisten
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2713568C (en) 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (de) 2008-03-21 2019-10-09 The University of Chicago Behandlung mit opioid-antagonisten und mtor-inhibitoren
KR20110004425A (ko) * 2008-05-07 2011-01-13 넥타르 테라퓨틱스 말초적 작용 오피오이드 길항제의 경구 투여
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP3939964A1 (de) 2008-12-31 2022-01-19 Ardelyx, Inc. Kombinationen zur inhibierung des nhe-vermittelten antiports bei der behandlung von mit flüssigkeitsretention und salzüberlastung assoziierten erkrankungen und erkrankungen des magen-darm-trakts
PT2405915T (pt) 2009-03-10 2019-01-29 Euro Celtique Sa Composições farmacêuticas de libertação imediata compreendendo oxicodona e naloxona
AU2010238925A1 (en) * 2009-04-22 2011-12-15 Phoeme Gmbh Particulate pharmaceutical composition having an opioid and an opioid antagonist
MX342548B (es) * 2009-09-18 2016-10-04 Merck Sharp & Dohme Corp * Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal.
JP5838199B2 (ja) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． 活性剤を含まない顆粒およびその顆粒を含む錠剤の製造
NZ603170A (en) 2010-05-10 2015-04-24 Euro Celtique Sa Combination of active loaded granules with additional actives
AU2013304812B2 (en) 2012-08-21 2016-06-09 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AU2013308403B2 (en) * 2012-08-29 2019-02-07 Salix Pharmaceuticals, Inc. Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP6377132B2 (ja) 2013-04-12 2018-08-22 アーデリクス，インコーポレーテッド Ｎｈｅ３結合化合物およびリン酸輸送の阻害方法
AU2014295042B2 (en) 2013-07-23 2017-03-30 Mundipharma Pty Limited A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
MX2016006279A (es) 2013-11-13 2016-09-07 Euro Celtique Sa Hidromorfona y naloxona para el tratamiento del dolor y el sindrome de disfuncion intestinal opiacea.
WO2016091805A2 (de) * 2014-12-08 2016-06-16 Develco Pharma Schweiz Ag Naloxon-monopräparat und mehrschichttablette
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
MA47207A (fr) 2017-01-09 2019-11-13 Ardelyx Inc Composés utiles pour le traitement de troubles du tractus digestif
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2023102491A1 (en) * 2021-12-01 2023-06-08 Invea Therapeutics, Inc. Methods for treating gastrointestinal inflammatory disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381877D1 (de) 1982-03-16 1990-10-18 Univ Rockefeller Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen.
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
IT1188550B (it) * 1986-02-07 1988-01-14 Sclavo Spa Peptide sintetico ad attivita' interleukina 1 umana
US4774230A (en) 1988-03-26 1988-09-27 Ivax Laboratories, Inc. Glucuronic acid derivatives of opioid antagonists
EP0647448A1 (de) 1993-10-07 1995-04-12 Euroceltique S.A. Oral verabreichbare, Opioid-Analgetika enthaltende Arzneimittel mit verlängerter Wirkung
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
GB9720797D0 (en) * 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
IT1298575B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di
CA2338031C (en) 1998-07-17 2006-12-05 Sankaram Bhima Mantripragada Biodegradable compositions for the controlled release of encapsulated substances
AU776567B2 (en) 1999-11-01 2004-09-16 Evans, Brian K Composition for treatment of constipation and irritable bowel syndrome

Also Published As

Publication number Publication date
AU1044701A (en) 2001-05-14
IL149378A0 (en) 2002-11-10
EP1225897A2 (de) 2002-07-31
CA2389650A1 (en) 2001-05-10
WO2001032180A2 (en) 2001-05-10
JP2003513045A (ja) 2003-04-08
ATE275402T1 (de) 2004-09-15
WO2001032180A3 (en) 2001-09-20
IL149378A (en) 2006-12-31
US6734188B1 (en) 2004-05-11
CA2389650C (en) 2008-12-09
DE60013630T2 (de) 2005-09-15
EP1225897B1 (de) 2004-09-08
PT1225897E (pt) 2005-01-31
CZ20021536A3 (cs) 2003-02-12
CZ299726B6 (cs) 2008-11-05
ES2226933T3 (es) 2005-04-01
AU776567B2 (en) 2004-09-16
DK1225897T3 (da) 2005-01-10
HK1048595A1 (en) 2003-04-11

Similar Documents

Publication Publication Date Title
DE60013630D1 (de) Arzneimittel zur behandlung von darmverstopfung und reizkolon
DE602004026604D1 (de) Pharmazeutische kombinationen von hydrocodon und naltrexon
ATE293610T1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
WO2003097608A3 (en) Opioid and opioid-like compounds and uses thereof
TR200100671T1 (tr) Antiviral indoloksoasetil piperazin türevleri
EP1783126A3 (de) N-Oxide von N-Phenyl-2-Pyrimidinamin Derivaten
ATE446751T1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
CY1105225T1 (el) Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας
HUP9800938A2 (hu) NK-1 receptor antagonisták alkalmazása irritációs bélszindróma tüneteinek kezelésére
ATE506959T1 (de) Verwendung von il-18 inhibitoren
HUP0204458A3 (en) Derivatives of quinoline as alpha-2 antagonists and pharmaceutical compositions containing them
EA200870449A1 (ru) Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами
ATE295174T1 (de) Arzneimittel zur behandlung von bluthochdruck
EE200100378A (et) Tuumorinekroositeguri antagonisti ning seda sisaldava farmatseutilise kompositsiooni kasutamine endometrioosi raviks
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
EE200200271A (et) Ravimkombinatsioonid ning nende kasutamine
ATE431142T1 (de) Arzneimittel zur behandlung und vermeidung neurogener schmerzen
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
ATE400277T1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
DE60311822D1 (de) Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen
NO20001894L (no) Anvendelse av TNF-antagonister som medikamenter for behandling av septiske sykdommer
FR2869539B1 (fr) Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose
AU2003231019A8 (en) Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use
ATE353221T1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa

Legal Events

Date Code Title Description
8364 No opposition during term of opposition